Stock Ratings / Health Care / CMPS / earnings

ANIP (70) STOK (59) NUVB (29) NBTX (52) ⌘ Pro Terminal →

COMPASS Pathways Plc American Depository Shares (CMPS) Next Earnings Date & Expected ±11.3% Move

$12.19 -0.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.15

COMPASS Pathways Plc American Depository Shares (CMPS) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.69B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.15 (-0.32%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CMPS)Realized 20D OHLCV Swing Band: ±11.3%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY CMPS SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$12.00-10.4% Next Q

Q2 (-2Q)

Grade E$10.75+4% Next Q

Q3 (-1Q)

Grade E$11.18+9% Next Q

Current

Grade D-$12.19-8.1% Hist 90D α

Trajectory: E (29) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CMPS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CMPS currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.91) and Max Pain ($12.80) forces dealer call-delta covering toward $16.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CMPS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CMPS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±11.3% Swing Band

±$1.38 Expected Swing

MODEL EARNINGS SETUP GAUGE

CMPS Quantitative Pre-Earnings Setup: 37/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (37/100)Model Risk Weight (63/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$269.8M	-$157.2M	52%
FY 2024	2024-12-31	$0	-$155.1M	-$119.2M	52%
FY 2023	2023-12-31	$0	-$118.5M	-$97.4M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CMPS)

✓Walkthrough of CMPS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CMPS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +34.55%📐 HORIZONTAL RANGE

2026-10-30O $11.82H $12.19L $11.27C $12.19VOL 2.17M

RES: $16.22SUP: $10.74SMA50: $12.91SMA200: $10.40

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CMPS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CMPS Butterfly Map → + Track CMPS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CMPS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CMPS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CMPS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CMPS)

Health Care Rank #739 of 1016 ⚔️ ANIP vs CMPS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CMPS vs. ANIP, STOK, NUVB, NBTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, COMPASS Pathways Plc American Depository Shares (CMPS) ranks #739 by composite RQD confidence (37/100, grade D-) and #288 by equity capitalization ($1.69B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with CMPS at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CMPS ACTIVE COMPASS Pathways Plc American Depository Shares	D-	37/100	—	—	-35.0%	-0.73%	$1.69B	Benchmark Subject
ANIP ANI Pharmaceuticals Inc.	B-	70/100	21.5x	—	16.0%	+2.02%	$1.68B	/anip-vs-cmps →
STOK Stoke Therapeutics Inc.	C-	59/100	—	—	-6.1%	-0.23%	$1.70B	/stok-vs-cmps →
NUVB Nuvation Bio Inc. (Class A)	E	29/100	—	—	-35.0%	+3.92%	$1.67B	/nuvb-vs-cmps →
NBTX Nanobiotix S.A.	D+	52/100	—	—	—	-0.53%	$1.72B	/nbtx-vs-cmps →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001816590

In its most recent audited fiscal period (FY2025, filed 2025-12-31), COMPASS Pathways Plc American Depository Shares (CMPS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$269.8M, operating cash flow of -$157.2M, and free cash flow of -$157.2M (-31.9% YoY). On the balance sheet, CMPS closed FY2025 with $210.3M in total assets against $14.1M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$269.8M	-$157.2M	-$157.2M	$210.3M	$14.1M
FY2024 (FY)	2024-12-31	$0	-$155.1M	-$119.2M	-$119.2M	$213.7M	$24.7M
FY2023 (FY)	2023-12-31	$0	-$118.5M	-$97.4M	-$97.4M	—	—

3. CMPS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CMPS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, COMPASS Pathways Plc American Depository Shares (NASDAQ: CMPS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $12.19 (-0.73% 1D, market cap $1.69B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CMPS ranks #739 in composite RQD confidence.

How does CMPS compare to ANIP and STOK in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMPS carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANIP (ANI Pharmaceuticals Inc.) holds a B- grade (70/100 RQD, P/E 21.5x, ROIC 16.0%, cap $1.68B) and STOK (Stoke Therapeutics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC -6.1%, cap $1.70B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CMPS?

Per CMPS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001816590), COMPASS Pathways Plc American Depository Shares generated $0 in revenue, -$269.8M in net income, and -$157.2M in free cash flow against $210.3M in total assets and $14.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CMPS trading relative to its 50-day, 200-day, and 52-week technical levels?

CMPS last traded at $12.19 (-0.73% on volume of 1,382,444 shares), positioning the stock -5.58% below its 50-day simple moving average ($12.91) and +17.21% above its 200-day simple moving average ($10.40). Across its 52-week range of $4.88 to $15.87, CMPS sits at the 66.5% percentile with a 14-day RSI of 45.5 (NEUTRAL RANGE) and an implied next-earnings move of ±11.3% ($10.81 to $13.57).

CMPS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is CMPS's next earnings date?

Based on SEC filing cadence, COMPASS Pathways Plc American Depository Shares (CMPS)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is CMPS stock expected to move on earnings?

Volatility modeling currently projects a ±11.3% event move for CMPS, spanning a range between $10.81 and $13.57.

Direct Sub-Reports: CMPS RQD Cockpit CMPS 12M Forecast CMPS Earnings & Move CMPS Dividends & DRIP CMPS Insiders & 13F CMPS Whale Options CMPS Profit Sankey CMPS News & Why